Inhibitory effect of statins on renal epithelial-to-mesenchymal transition

American Journal of Nephrology

Volumn 26, Issue 4, 2006, Pages 381-387

  Patel, Sharmila ^a   Mason, Roger M ^b   Suzuki, Jun ^c   Imaizumi, Atsushi ^c   Kamimura, Takashi ^c   Zhang, Zhi ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c TEIJIN PHARMA LIMITED   (Japan)

Author keywords

Epithelial to mesenchymal transition; Isoprenylation; Rac1 activation; Renal fibrosis; RhoA activation; Small RhoGTPase; Statins

Indexed keywords

CYTOKERATIN 19; ECTODYSPLASIN A; GERANYLGERANYL PYROPHOSPHATE; ISOPRENOID; MEVINOLIN; PRAVASTATIN; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; UVOMORULIN;

ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; KIDNEY INTERSTITIUM; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

CELL DIFFERENTIATION; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY TUBULES, PROXIMAL; MESENCHYMAL STEM CELLS;

EID: 33748676495     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094780     Document Type: Article

References (22)

1. Kalluri R, Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776-1784.
2. Liu Y: Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004;15:1-12.
3. Healy E, Leonard M, Madrigal-Estebas L, O'Farrelly C, Watson AJ, Ryan MP: Factors produced by activated leukocytes alter renal epithelial cell differentiation. Kidney Int 1999;56:1266-1269.
4. Nightingale J, Patel S, Suzuki N, Buxton R, Takagi KI, Suzuki J, Sumi Y, Imaizumi A, Mason RM, Zhang Z: Oncostatin M, a cytokine released by activated mononuclear cells, induces epithelial cell-myofibroblast transdifferentiation via Jak/Stat pathway activation. J Am Soc Nephrol 2004;15:21-32.
5. Patel S, Takagi KI, Suzuki J, Imaizumi A, Kimura T, Mason RM, Kamimura T, Zhang Z: RhoGTPase activation is a key step in renal epithelial mesenchymal transdifferentiation. J Am Soc Nephrol 2005;16:1977-1984.
6. Olofsson B: Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell Signal 1999;11:545-554.
7. Boettner B, Van Aelst L: The role of Rho GTPases in disease development. Gene 2002;286:155-174.
8. Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 2000;101:207-213.
9. Kim SI, Han DC, Lee HB: Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 2000;11:80-87.
10. Park JK, Müller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, Bieringer M, Schäfer O, Lindschau C, Schneider W, Ganten D, Luft FC, Haller H: Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int 2000;58:1420-1430.
11. Li C, Yang CW, Park JH, Lim SW, Sun BK, Jung JY, Kim SB, Kim YS, Kim J, Bang BK: Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 2004;286:F46-F57.
12. Vieira JM Jr, Mantovani E, Rodrigues LT, Delle H, Noronha IL, Fujihara CK, Zatz R: Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrol Dial Transplant 2005;20:1582-1591.
13. Rikitake Y, Liao JK: Rho GTPases, statins and nitric oxide. Circ Res 2005;97:1232-1235.
14. Van Aelst L, D'Souza-Schorey C: Rho GTP-ases and signaling networks. Genes Dev 1997;11:2295-2322.
15. Laufs U, Liao JK: Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 2000;10:143-148.
16. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Limdquist CA, Engel ME, Arteaga CL, Moses HL: Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 2001;12:27-36.
17. Royal I, Lamarche-Vane N, Lamorte L, Kaibuchi K, Park M: Activation of Cdc42, Rac, PAK, and Rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation. Mol Biol Cell 2000;11:1709-1725.
18. Zondag GC, Evers EE, ten Klooster JP, Janssen L, van der Kammen RA, Collard JG: Oncogenic Ras downregulates Rac activity, which leads to increased Rho activity and epithelial-mesenchymal transition. J Cell Biol 2000;149:775-781.
19. Chen HC, Guh JY, Shin SJ, Tomino Y, Lai YH: Effects of pravastatin on superoxide and fibronectin production of mesangial cells induced by low-density lipoprotein. Kidney Blood Press Res 2002;25:2-6.
20. Eberlein M, Heusinger-Ribeiro J, Goppelt-Struebe M: Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001;133:1172-1180.
21. 3K. Nature 1997;390:632-636.
22. Sander EE, ten Klooster JP, van Delft S, van der Kammen RA, Collard JG: Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behaviour. J Cell Biol 1999;147:1009-1022.